Predictions
Drägerwerk AG & Co. KGaA VZO
Start price
Target price
Perf. (%)
€61.80
08.03.21
08.03.21
-
08.03.22
08.03.22
-21.91%
09.03.22
09.03.22
Drägerwerk AG & Co. KGaA ST
Start price
Target price
Perf. (%)
€61.80
08.03.21
08.03.21
-
08.03.22
08.03.22
-26.29%
09.03.22
09.03.22
Bayer AG ADR
Start price
Target price
Perf. (%)
€13.10
08.03.21
08.03.21
€14.00
3.05%
10.03.21
10.03.21
EBIT growth >5% per year expected
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Vivani Medical Inc.
Start price
Target price
Perf. (%)
€24.00
08.03.21
08.03.21
€15.00
08.03.22
08.03.22
32.50%
20.03.21
20.03.21
Good rating
Capable Management
Probably not worthwhile Investment
No Innovation
Aphria Inc.
Start price
Target price
Perf. (%)
€13.38
08.03.21
08.03.21
€15.00
13.62%
10.03.21
10.03.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
MorphoSys AG
Start price
Target price
Perf. (%)
€82.98
08.03.21
08.03.21
-
08.03.22
08.03.22
-72.98%
09.03.22
09.03.22
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Good rating
Standard Investments for future growth
Riot Blockchain Inc.
Start price
Target price
Perf. (%)
€36.19
07.03.21
07.03.21
-
07.03.22
07.03.22
-62.14%
08.03.22
08.03.22
EBIT growth >5% per year expected
Capable Management
Could be worthwhile Investment >10% per year
Little innovation
X T L Biopharmaceuticals Ltd ADR
Start price
Target price
Perf. (%)
€2.80
06.03.21
06.03.21
-
06.03.22
06.03.22
-25.00%
07.03.22
07.03.22
Could be very worthwhile Investment >20% year
Stratec SE
Start price
Target price
Perf. (%)
€116.60
03.03.21
03.03.21
€165.00
03.10.22
03.10.22
3.43%
06.04.22
06.04.22
Could be worthwhile Investment >10% per year
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€57.94
01.03.21
01.03.21
-
01.03.22
01.03.22
-2.93%
02.03.22
02.03.22
Zoetis Inc. A
Start price
Target price
Perf. (%)
€130.34
27.02.21
27.02.21
-
27.02.22
27.02.22
37.81%
20.01.22
20.01.22
Innovative
Medium risks for its business
Top 10 in its market
Future proof or reliable business model
Incyte Corp.
Start price
Target price
Perf. (%)
€64.63
25.02.21
25.02.21
€70.00
3.84%
08.03.21
08.03.21
Could be worthwhile Investment >10% per year
Incyte Corp.
Start price
Target price
Perf. (%)
€67.64
24.02.21
24.02.21
-
24.02.22
24.02.22
-12.39%
25.11.21
25.11.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
Hologic Inc.
Start price
Target price
Perf. (%)
€62.50
24.02.21
24.02.21
-
24.02.22
24.02.22
1.60%
30.03.21
30.03.21
Probably not worthwhile Investment
Viracta Therapeutics Inc.
Start price
Target price
Perf. (%)
€15.09
23.02.21
23.02.21
-
23.02.22
23.02.22
18.33%
24.02.21
24.02.21
Innovative
Could be worthwhile Investment >10% per year
Good culture
No uniques
Astrazeneca ADR
Start price
Target price
Perf. (%)
€41.40
22.02.21
22.02.21
-
22.02.22
22.02.22
0.00%
10.03.21
10.03.21
Could be worthwhile Investment >10% per year
Medium risks for its business
Small cyclical dependencies
Celsion Corp.
Start price
Target price
Perf. (%)
€35.70
22.02.21
22.02.21
€60.00
22.02.22
22.02.22
-37.40%
06.03.21
06.03.21
Could be worthwhile Investment >10% per year
Good culture
Leading role in innovation
high free float
Teleflex Inc.
Start price
Target price
Perf. (%)
€320.00
21.02.21
21.02.21
-
21.02.22
21.02.22
14.38%
23.04.21
23.04.21
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Low dividend yield expected
Heidelberg Pharma AG
Start price
Target price
Perf. (%)
€8.98
21.02.21
21.02.21
€10.00
21.02.22
21.02.22
-54.90%
22.02.22
22.02.22
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Known brand
Very Future proof/growth oriented business model
Vita 34 AG
Start price
Target price
Perf. (%)
€15.55
21.02.21
21.02.21
-
21.02.22
21.02.22
-25.08%
22.02.22
22.02.22
Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.22
21.02.21
21.02.21
-
21.02.22
21.02.22
-5.21%
06.03.21
06.03.21
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Inovio Pharma
Start price
Target price
Perf. (%)
€11.30
20.02.21
20.02.21
€6.80
20.02.22
20.02.22
-38.75%
10.07.21
10.07.21
Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€23.36
20.02.21
20.02.21
€26.40
20.02.22
20.02.22
-34.73%
06.05.21
06.05.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year